Drug profile · INN
rapacuronium bromide
RAPLON
rapacuronium bromide (RAPLON) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — rapacuronium bromide
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
rapacuronium bromide (RAPLON) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
Primary target: Muscle-type nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is rapacuronium bromide?
rapacuronium bromide (RAPLON) is a muscle-type nicotinic acetylcholine receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for rapacuronium bromide?
RAPLON is a marketed brand name for rapacuronium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rapacuronium bromide?
rapacuronium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.